Therapeutics Stabilized Red Blood Cell Levels in Patients With a Rare Blood Cancer, Positioning It to Compete With a Takeda Pharmaceuticals

In the 48-person Phase 2 trial, 88% of patients who received divesiran every six or 12 weeks achieved a clinical response, versus 19% on placebo, the company said Monday. Polycythemia vera is marked by runaway red blood cell production, putting patients at risk of life-threatening clots, bleeds, and other cancers. The full story is available to STAT+ subscribers.